Journal of Thoracic Disease · 2022 · 10 citations · 18 references
Life SciencesMolecular BiologyPharmacologyCell SignalingGene ExpressionSignal TransductionCytokine BiologyCytokine Receptor SignalingCytokine SignalingFibrosisInflammatory SignalingInterstitial Lung DiseaseCell Proliferation IndicesCell Viability AssaysConnective Tissue Disease - Associated Interstitial Lung DiseaseConnective Tissue Disease-associated Interstitial Lung DiseaseProtein Expression LevelsReverse Transcription Polymerase Chain Reaction (Rt-pcr)Stat3 SignalingWestern Blotting
Background: To explore the effect and mechanism of pirfenidone in inhibiting pulmonary fibrosis in connective tissue disease-associated interstitial lung disease (CTD-ILD). Methods: experiments, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests were used to evaluate cell proliferation, Reverse Transcription-Polymerase Chain Reaction(RT-PCR) was performed to detect STAT3 and KL-6 mRNA expression levels, ELISA was utilized to detect TNF-α and E-cadherin expression levels, and Western blotting (WB) was performed to determine α-smooth muscle actin (α-SMA), vimentin, TNF-α, STAT3, phosphorylated signal transducer and activator of transcription 3 (PSTAT3) and KL-6 expression. Results: experiments, the α-SMA, vimentin, STAT3 and KL-6 levels in the treatment group were significantly lower than those in the bleomycin group (P<0.05). Compared with those in the pirfenidone group, the α-SMA, vimentin, STAT3 and KL-6 levels in the TNF-α-treated group were significantly upregulated (P<0.05). Meanwhile, cell viability was further upregulated (P<0.05), and the expression of STAT3 and KL-6 was further decreased in the Stattic-treated group (P<0.05). In the group treated with infliximab combined with Stattic, TNF-α expression was significantly increased (P<0.05), cell activity was significantly restored (P<0.05), and the STAT3, KL-6 and E-cadherin expression levels were inhibited (P<0.05). Conclusions: Pirfenidone improved pulmonary function 1 and decreased TNF-α, STAT3, and KL-6 expression in CTD-ILD patients. Moreover, pirfenidone inhibits cell fibrosis through the TNF-α/STAT3/Mucin 1(MUC1) pathway.
18
Jie Zhang, Dan Wang, Lei Wang et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2019 · 200 citations · Full text
Fateme Pourgholamhossein, Rokhsana Rasooli, Mostafa Pournamdari et al. · Food and Chemical Toxicology · 2017 · 99 citations
Medicine, Pharmacology, Toxicology +17